Comparative guide · 6 min read

Black Cohosh vs Red Clover for menopause — what the head-to-head evidence actually shows

Updated 2026-05-17 · Reviewed by SupplementScore editors · No sponsorships

Black cohosh (Actaea racemosa) and red clover (Trifolium pratense) are the two most-marketed non-hormonal herbs for menopausal hot flashes. They have very different mechanisms (or proposed mechanisms): black cohosh appears to act centrally on serotonergic/dopaminergic pathways rather than via estrogen receptors, while red clover is an isoflavone source with weak phytoestrogen activity. Cochrane and meta-analytic data favour black cohosh (modestly) for vasomotor symptoms; red clover's trial results are largely null. Neither is a substitute for menopausal hormone therapy in candidates who are good candidates for it.

Quick verdict

GoalBetter choiceWhy
Hot flashes / night sweatsBlack cohosh (modest)Meta-analyses show ~25% reduction in frequency vs placebo; red clover trials are largely null.
Hormone-receptor-positive cancer survivorsBlack cohosh (with oncology input)Not estrogenic in standard assays; red clover isoflavones are weakly estrogenic and generally avoided.
Sleep disturbance due to night sweatsBlack cohoshIndirect via hot-flash reduction; red clover hasn't reliably shown sleep benefit.
Mood symptoms in perimenopauseNeitherSaffron, omega-3 EPA, and SSRIs have better evidence; both herbs are at best modest.
Vaginal/genitourinary symptomsNeitherLocal vaginal estrogen is the treatment of choice; neither herb addresses this.
Bone preservationNeitherEstrogen, bisphosphonates, and resistance training drive bone outcomes; both herbs have weak/inconsistent evidence.

How they actually work

Black cohosh — centrally acting, not classically estrogenic

Older marketing framed black cohosh as a "phytoestrogen." More recent pharmacology suggests it acts on central serotonergic and dopaminergic pathways relevant to thermoregulation rather than via estrogen receptor activation. It does not appear to stimulate breast or endometrial tissue in standard preclinical assays. The most-studied preparation is the standardised Remifemin extract (1 mg triterpene glycosides per tablet, dosed BID).

Red clover — isoflavones with weak estrogenic activity

Red clover is rich in isoflavones (biochanin A, formononetin, daidzein, genistein), which are weakly estrogenic and bind preferentially to estrogen receptor beta. Commercial extracts (e.g., Promensil) are standardised to total isoflavones, typically 40–80 mg/day. The premise is that isoflavones partially substitute for declining endogenous estrogen, but the trial evidence has been disappointing.

Hot flashes — the most-trialled endpoint

Black cohosh: meta-analyses (Leach 2012 Cochrane, Castelo-Branco 2021) show modest reductions in hot-flash frequency vs placebo — typically ~25% reduction over 12–24 weeks. Effect is smaller than menopausal hormone therapy and smaller than SNRIs (paroxetine, venlafaxine), but real. Red clover: the 2013 Cochrane review and several large RCTs (Tice 2003, ICE trial) did not show a clinically meaningful reduction in hot-flash frequency over placebo. Some newer trials with higher isoflavone doses or specific biochanin-A-enriched extracts show small effects, but the overall picture is weak.

Liver safety and black cohosh

Case reports of hepatotoxicity have driven regulatory warnings on black cohosh (EMA 2006, Australia's TGA, Health Canada). Causality has been disputed — large pharmacovigilance reviews suggest the actual incidence is low and possibly confounded by product adulteration. Reasonable practice: use a standardised, reputable preparation; avoid in pre-existing liver disease; discontinue and seek evaluation for jaundice, dark urine, or abdominal pain.

Cancer history and hormonally sensitive disease

Red clover's isoflavones are weakly estrogenic and are generally avoided in women with hormone-receptor-positive breast cancer history. Black cohosh, despite older "phytoestrogen" framing, does not appear to promote breast or endometrial tissue and has been studied (mostly safely) in breast cancer survivors on tamoxifen — but discuss with oncology before starting any supplement.

Practical rule. For mild-to-moderate hot flashes in someone who can't or doesn't want hormone therapy, black cohosh (Remifemin or equivalent, 40 mg/day standardised extract) for 12 weeks is a reasonable trial. Red clover is the weaker option and is best skipped for the indication it's marketed for. Neither replaces a real conversation about hormone therapy if you're a candidate.

Dose, form, and timing

Black cohosh: 40 mg/day standardised extract (e.g., Remifemin 20 mg BID, providing 1 mg triterpene glycosides per tablet). Allow 8–12 weeks for full effect. Don't combine multiple "menopause blend" products that all contain black cohosh.

Red clover: 40–80 mg total isoflavones/day standardised extract. Trial duration in studies has been 12–24 weeks. Higher doses have not consistently produced better outcomes.

Safety

Black cohosh: hepatotoxicity warnings (low absolute risk; review for signs of liver injury). Mild GI symptoms in some users. Pregnancy/lactation: avoid.

Red clover: GI symptoms. Theoretical concern with anticoagulants (coumarin content). Generally avoid in hormone-receptor-positive cancer history without oncology input. Pregnancy/lactation: avoid.

What about the wider non-hormonal menopause toolkit?

Better-evidenced non-hormonal options for hot flashes include paroxetine (FDA-approved for vasomotor symptoms), venlafaxine, gabapentin, oxybutynin, and the newer NK3-receptor antagonist fezolinetant. Cognitive behavioural therapy for hot-flash bother (CBT-Meno) is the best non-drug evidence. Soy isoflavones (genistein-rich extracts) have somewhat better evidence than red clover for hot-flash reduction. The supplement layer is the smallest part of a good menopause plan.

Who should pick each

Pick black cohosh if: hot flashes are mild-to-moderate, hormone therapy isn't appropriate or wanted, you can commit to 8–12 weeks of consistent use, you don't have liver disease, you can use a standardised reputable preparation.

Pick red clover if: you specifically want a phytoestrogen-style intervention and tolerate the weaker evidence, you don't have hormone-sensitive cancer history. (For most uses, soy-based isoflavone products have somewhat better data.)

Pick neither if: you're a candidate for menopausal hormone therapy and haven't had that conversation, your dominant symptoms are vaginal dryness/dyspareunia (use local estrogen), or symptoms are severe.

What we'd actually buy

For mild-to-moderate vasomotor symptoms in someone who can't or won't use hormone therapy: Remifemin (or equivalent standardised black cohosh) 40 mg/day for 12 weeks, alongside CBT-based bother-reduction strategies, dressing in layers, paced respiration, and reducing alcohol. Reassess at 12 weeks; if no benefit, discontinue.

Sources

Read more: